Novo EVP: Negotiations can begin now

Following approval of diabetes combo Xultophy and announcement of a list price, the head of Novo Nordisk’s US business can start negotiating with payers, who might be looking to play the company off against its rival Sanofi. “We won’t necessarily navigate based on what Sanofi decides,” says Jakob Riis.

Foto: Mikkel Berg Pedersen

Novo Nordisk is not targeting a broad launch of its newly approved combination product Xultophy when it is commercialized in the US next year, but will rather go for a more narrow patient population. This is according to the head of the pharma group’s US business, Jakob Riis.

“It’s an important approval for us, as it is a product with strong clinical qualities; a product that we plan to launch in a well-defined patient population – i.e. the ones who need and can benefit the most from the intensification it gives when you combine a basal insulin and a GLP-1 in one injection. It will be a focused launch in the US in H1 next year,” he tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier